The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with NRAS wild-type or mutant melanoma from a phase I study.
Julie Ann Means-Powell
No relevant relationships to disclose
Alex A. Adjei
Honoraria - Daiichi Sankyo
Research Funding - Ardea Biosciences; Bayer; Pfizer; Syndax
Igor Puzanov
No relevant relationships to disclose
Grace K. Dy
No relevant relationships to disclose
Laura Williams Goff
No relevant relationships to disclose
Wen Wee Ma
No relevant relationships to disclose
Gerald J. Fetterly
No relevant relationships to disclose
Shaunita A. Michael
No relevant relationships to disclose
Feng Chai
Employment or Leadership Position - ArQule
Stock Ownership - ArQule
Maria Lamar
Employment or Leadership Position - ArQule
Stock Ownership - ArQule
Brian E. Schwartz
Employment or Leadership Position - ArQule
Stock Ownership - ArQule
Jeffrey Alan Sosman
No relevant relationships to disclose